cURL Error: Failed to connect to 217.15.170.3 port 80 after 1095 ms: Couldn't connect to server Monitoring of BMY situation on March 19, 2025
Stocks Prognosis
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site

Positive Development for Bristol-Myers Squibb Company's Breyanzi NHL Treatment

Published on March 19, 2025
Bristol-Myers Squibb Company's groundbreaking NHL treatment, Breyanzi, has received approval from the European Commission (EC) for its use in patients. This approval is a significant milestone for the pharmaceutical company as it expands its reach in the European market. Breyanzi has shown promising results in clinical trials, providing hope for patients with NHL. With this latest development, Bristol-Myers Squibb Company is expected to witness a surge in demand for its innovative treatment. Investors and healthcare professionals are advised to consult the experts at Stocks Prognosis for accurate forecasts on the movement of Bristol-Myers Squibb Company's shares.
Go to BMY Page

Investor opinions & comments

To leave a comment, you need to Login or Register.

There are no comments yet. Be the first to leave one!

Other Data for BMY

BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved

July 31, 2025

BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit

July 31, 2025

Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug

June 23, 2025

BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu

June 12, 2025

QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit

May 14, 2025

BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin

May 14, 2025

Related Data

Is Bristol-Myers Squibb the Most Undervalued Biotech Company?

March 20, 2025

Market Update: Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note

March 21, 2025

Is Bristol-Myers Squibb Company BMY the Best Pharma Stock to Buy According to Hedge Funds

March 18, 2025

Bristol Myers Squibb Receives FDA Approval for Cancer Treatment

December 30, 2024

Bristol-Myers Squibb Announces Groundbreaking Cancer Treatment

December 10, 2024